Research Topics
| L M KrugSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinomaLee M Krug
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 104:2149-55. 2005..In the current study, the authors combined trastuzumab with weekly taxanes in an attempt to improve outcomes over standard chemotherapy in patients with advanced NSCLC...- An overview of chemotherapy for mesotheliomaLee M Krug
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Hematol Oncol Clin North Am 19:1117-36, vii. 2005..The role of treatment in various disease settings and the difficulty in assessing the benefit of that therapy is discussed. Finally, an update is provided on novel therapeutics being testing in mesothelioma... - Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acidLee M Krug
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Lung Cancer 7:257-61. 2006.... - Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trialLee M Krug
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 103:2128-31. 2005..The authors conducted a Phase II single-institution study of imatinib in patients with recurrent SCLC whose tumor specimens expressed c-kit protein... - Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyaninLee M Krug
Thoracic Oncology Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:6094-100. 2004..A prior clinical study demonstrated the potent immunogenicity of fucosyl GM-1 derived from bovine thyroid gland, conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 adjuvant... - Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesotheliomaLee M Krug
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
J Thorac Oncol 2:317-20. 2007..In mesothelioma cell lines and xenografts, pralatrexate demonstrated significant antitumor activity... - Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levelsLee M Krug
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10021, USA
J Thorac Oncol 2:947-52. 2007..A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies... - Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesotheliomaLee M Krug
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 27:3007-13. 2009.... - 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancerLee M Krug
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University New York, New York 10021, USA
Clin Cancer Res 9:2072-8. 2003..The recommended Phase II dose was 150 mg/m(2) i.v. every 2 weeks. Responses observed in patients with non-small cell lung cancer (NSCLC) in the Phase I trial prompted this Phase II trial... - WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancerLee M Krug
Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY, 10065, USA
Cancer Immunol Immunother 59:1467-79. 2010..We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1... - Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococciLee M Krug
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave, New York, NY 10065, USA
Cancer Immunol Immunother 61:9-18. 2012..The objectives of the current trial were to establish the lowest optimal dose and to confirm the safety of the induction of antibodies against polySA with the NP-polySA vaccine... - Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolateL M Krug
Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 6:3493-8. 2000..These studies will also quantitate the expression of genes controlling internalization (RFC-1) and polyglutamylation of PDX in tumor cells as correlates of response... - Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancerLee M Krug
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
J Thorac Oncol 6:384-6. 2011.... - Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbineLee M Krug
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
Lung Cancer 39:139-43. 2003..In conclusion, bcl-2 and bax expression was similar in this population with advanced NSCLC to previously reported results for early stage disease, but did not predict response to vinorelbine plus docetaxel in this series... - Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancerV A Miller
Thoracic Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
J Clin Oncol 18:1346-50. 2000..We show that docetaxel (60 mg/m(2)) and vinorelbine (45 mg/m(2)) can be safely combined when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed... - Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyaninLee M Krug
Thoracic Oncology Service and Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Clin Cancer Res 10:916-23. 2004..We plan to incorporate this vaccine as a component of a polyvalent vaccine with GM2, fucosylated GM1, and Globo H to target SCLC... - A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerDaniel T Milton
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 107:1034-41. 2006..The 5% objective response rate did not reach the stated objective at the interim efficacy analysis, prompting the closure of the study... - Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapyVishal Gupta
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
J Thorac Oncol 4:746-50. 2009.... - Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapyP O Livingston
Department of Medicine, Clinical Immunology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer Immunol Immunother 54:1018-25. 2005..These findings support our plan to develop a tetravalent vaccine against SCLC targeting GM2, fucosyl GM1, globo H and polysialic acid... - A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignanciesPaul K Paik
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Chemother Pharmacol 66:1079-85. 2010.... - Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 21:2094-100. 2003..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients... - A phase I trial of perillyl alcohol in patients with advanced solid tumorsChristopher G Azzoli
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer Chemother Pharmacol 51:493-8. 2003..This phase I trial was conducted to determine the optimal dose of perillyl alcohol... - Surgery in the management of small cell lung cancerRobert J Downey
Division of Thoracic Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Natl Compr Canc Netw 2:159-62. 2004..However, a small number of patients present with resectable disease, and this review summarizes the available literature addressing the possible role for surgery in the treatment of these patients... - A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumorsMatthew G Fury
Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
Cancer Chemother Pharmacol 57:671-7. 2006..Vitamin B(12) and folate supplementation may allow for further dose escalation of pralatrexate and probenecid. This is a suitable question for a future study... - Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemiaPeter G Maslak
Leukemia Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Blood 116:171-9. 2010..Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia... - Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scansFan Liu
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, Columbia University, New York, New York
J Thorac Oncol 5:879-84. 2010.... - Trastuzumab in the treatment of non-small cell lung cancerChristopher G Azzoli
Department of Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 29:59-65. 2002..Whether trastuzumab will show a clear benefit for patients with NSCLC, either alone or in combination with established chemotherapy, remains to be proven in phase III testing... - The evolution of multimodality therapy for malignant pleural mesotheliomaMarjorie G Zauderer
Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Curr Treat Options Oncol 12:163-72. 2011..Clearly, MPM requires a multidisciplinary approach and, due to the myriad of open questions, much effort continues to focus on identifying the optimal combination of surgery, chemotherapy, and radiation... - Gemcitabine-induced peripheral edema: report on 15 cases and review of the literatureChristopher G Azzoli
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Am J Clin Oncol 26:247-51. 2003..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine... - Targeting lethal minimal residual disease in small cell lung cancerJyoti D Patel
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Oncol 30:79-85. 2003..This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy... - A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancerChristopher G Azzoli
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
J Thorac Oncol 2:638-44. 2007..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer... - Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerWilliam Kevin Kelly
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Oncol 23:3923-31. 2005..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer... - Pulmonary neuroendocrine tumors: What (little) do we know?Lin Chi Chen
Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Natl Compr Canc Netw 4:623-30. 2006..This article discusses the current understanding of the epidemiology, pathologic characteristics, treatment, and prognosis of this spectrum of diseases... - Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancerVincent A Miller
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:1103-9. 2004..Phase II trials suggested female sex and adenocarcinoma were associated with response. We undertook this analysis to identify additional clinical and pathologic features associated with sensitivity to gefitinib... - Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancerLin Chi Chen
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Ave, New York, NY, United States
Lung Cancer 67:216-20. 2010..We conducted this study to determine if GD2/GM2 synthase RNA could be detected in SCLC cell lines and human tissues, and whether mRNA transcript levels corresponded with disease status... - Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trialRaja M Flores
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Thorac Oncol 1:289-95. 2006..We designed this clinical trial to test the feasibility of induction chemotherapy followed by EPP and RT in locally advanced MPM with the ultimate aim of improving survival... - A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumorsChristopher G Azzoli
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 13:2692-8. 2007..This phase 1 study was designed to determine the maximum tolerated dose and toxicity of pralatrexate plus paclitaxel or docetaxel in patients with advanced cancer... - Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancerDaniel T Milton
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
Cancer 110:599-605. 2007..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)... - Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trialsPaul K Paik
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Thorac Oncol 5:275-9. 2010.... - A phase I trial of SJG-136 (NSC#694501) in advanced solid tumorsYelena Y Janjigian
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, USA
Cancer Chemother Pharmacol 65:833-8. 2010..We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor... - Vaccine therapy for small cell lung cancerLee M Krug
Department of Medicine, Memorail Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
Semin Oncol 31:112-6. 2004..To optimize an immune response against a broad range of tumor phenotypes, these components will be combined into a polyvalent vaccine. A randomized phase II trial of this polyvalent vaccine is planned to start in 2004... - The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin diseaseScott A Laurie
Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 95:119-26. 2002..Patients who are diagnosed with HD should abstain from smoking. Physicians should assess specifically the smoking status of all HD patients and prescribe a smoking cessation program... - Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinomaFaye M Johnson
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA
Cancer 106:366-74. 2006..The decreased irinotecan clearance may explain the high incidence of diarrhea and neutropenia noted in the current study...